Entheon to Undergo Reverse Takeover by Nutravisor in Pivot to STRYK Brands

Entheon Biomedical ( (TSE:ENBI) ) has issued an update.

Entheon Biomedical has signed a definitive business combination agreement with Nutravisor Inc. under which Nutravisor will complete a reverse takeover of Entheon via a three-cornered amalgamation, resulting in Entheon acquiring all Nutravisor securities and subsequently operating under the Nutravisor business and the STRYK Brands name. The deal, which constitutes a Fundamental Change under Canadian Securities Exchange rules, values Nutravisor at $40 million, includes a share consolidation of Entheon, planned Nutravisor equity financings of at least $4 million and up to $10 million, the issuance of roughly 53.3 million post-consolidation Entheon shares to Nutravisor shareholders based on a fixed exchange ratio, lock-up provisions on those shares, and is conditional on CSE approval, shareholder approvals, completion of the financings, and other customary closing conditions.

The most recent analyst rating on (TSE:ENBI) stock is a Hold with a C$0.10 price target. To see the full list of analyst forecasts on Entheon Biomedical stock, see the TSE:ENBI Stock Forecast page.

Spark’s Take on TSE:ENBI Stock

According to Spark, TipRanks’ AI Analyst, TSE:ENBI is a Neutral.

The score is primarily held back by very weak financial performance (minimal revenue, ongoing losses, and cash burn despite no debt). Technicals are only mildly supportive with a short-term rebound but the stock remains below its 200-day average. The transformative acquisition/pivot provides potential upside but carries significant execution and dilution/approval risk, and valuation support is limited given losses and no dividend.

To see Spark’s full report on TSE:ENBI stock, click here.

More about Entheon Biomedical

Entheon Biomedical Corp. is a Toronto-based life sciences company listed on the CSE, OTCQB and FSE that has historically operated in the psychedelic and biomedical space. Through the announced transaction, it plans to pivot into the nutraceutical and performance-focused consumer health market by adopting Nutravisor Inc.’s portfolio of nutraceutical products and Nixodine-branded pouches aimed at health, performance and longevity consumers.

Average Trading Volume: 17,679

Technical Sentiment Signal: Sell

Current Market Cap: C$1.39M

See more data about ENBI stock on TipRanks’ Stock Analysis page.